February 17, 2025
2 min watch
Save
VIDEO: Results of AMPLIFY trial ‘biggest splash’ for front-line treatment of CLL
SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.
The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca) plus venetoclax (Venclexta, AbbVie) with or without obinutuzumab (Gazyva, Genentech) versus chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia.
“This is a really important study because it hopefully will lead to FDA approval of one or two of these combinations that are either an all-oral regimen or our first triplet regimen," Woyach, professor in the division of hematology at The Ohio State University, said.
Reference:
- Brown JR, et al. Abstract 1009. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Woyach reports serving in consulting roles for AstraZeneca, AbbVie, Genentech, Janssen, Loxo Lilly, Merck, Newave Pharmaceutical, Pharmacyclics and Schrödinger.
Read more about